CL2014003034A1 - Dispersion en polvo proliposomal que comprende terstosterona, colesterol y al menos un fosfolipido; una forma de dosificacion oral; y su uso en una terapia de testosterona - Google Patents

Dispersion en polvo proliposomal que comprende terstosterona, colesterol y al menos un fosfolipido; una forma de dosificacion oral; y su uso en una terapia de testosterona

Info

Publication number
CL2014003034A1
CL2014003034A1 CL2014003034A CL2014003034A CL2014003034A1 CL 2014003034 A1 CL2014003034 A1 CL 2014003034A1 CL 2014003034 A CL2014003034 A CL 2014003034A CL 2014003034 A CL2014003034 A CL 2014003034A CL 2014003034 A1 CL2014003034 A1 CL 2014003034A1
Authority
CL
Chile
Prior art keywords
terstosterone
phospholipid
cholesterol
dosage form
oral dosage
Prior art date
Application number
CL2014003034A
Other languages
English (en)
Inventor
Guru V Betageri
Ramachandran Thirucote
Veeran Gowda Kadajji
Original Assignee
Univ Western Health Sciences
Tesorx Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49551459&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014003034(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Western Health Sciences, Tesorx Pharma Llc filed Critical Univ Western Health Sciences
Publication of CL2014003034A1 publication Critical patent/CL2014003034A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
CL2014003034A 2012-05-09 2014-11-07 Dispersion en polvo proliposomal que comprende terstosterona, colesterol y al menos un fosfolipido; una forma de dosificacion oral; y su uso en una terapia de testosterona CL2014003034A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261644996P 2012-05-09 2012-05-09

Publications (1)

Publication Number Publication Date
CL2014003034A1 true CL2014003034A1 (es) 2015-07-03

Family

ID=49551459

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014003034A CL2014003034A1 (es) 2012-05-09 2014-11-07 Dispersion en polvo proliposomal que comprende terstosterona, colesterol y al menos un fosfolipido; una forma de dosificacion oral; y su uso en una terapia de testosterona

Country Status (32)

Country Link
US (5) US8957053B2 (es)
EP (1) EP2846781B1 (es)
JP (3) JP6055088B2 (es)
KR (1) KR20150032939A (es)
CN (2) CN104780914B (es)
AP (1) AP2014008099A0 (es)
AR (1) AR091006A1 (es)
AU (2) AU2013259509B2 (es)
BR (1) BR112014027942A2 (es)
CA (1) CA2872779A1 (es)
CL (1) CL2014003034A1 (es)
CO (1) CO7240373A2 (es)
CR (1) CR20140561A (es)
DO (1) DOP2015000026A (es)
EA (2) EA201791738A1 (es)
EC (1) ECSP14030572A (es)
GE (1) GEP201706754B (es)
HK (2) HK1210409A1 (es)
IL (1) IL235464B (es)
IN (1) IN2014DN10383A (es)
MA (1) MA37610B1 (es)
MX (1) MX367123B (es)
MY (1) MY175305A (es)
NZ (2) NZ702634A (es)
PE (1) PE20150203A1 (es)
PH (1) PH12014502498A1 (es)
SG (2) SG11201407349UA (es)
TN (1) TN2014000467A1 (es)
TW (2) TWI614035B (es)
UA (1) UA115058C2 (es)
WO (1) WO2013170012A2 (es)
ZA (2) ZA201408996B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10213440B2 (en) 2014-08-20 2019-02-26 Professional Compounding Centers Of America (Pcca) Oral transmucosal pharmaceutical compositions including testosterone and an aromatase inhibitor
KR101682821B1 (ko) 2015-07-21 2016-12-06 서울대학교산학협력단 프로리포솜 제조방법
WO2017120586A1 (en) * 2016-01-07 2017-07-13 Western University Of Health Sciences Formulations for treating bladder cancer
EP3399965A4 (en) * 2016-01-08 2019-08-21 Western University Of Health Sciences PROLIPOSOMAL TESTOSTERONE ANDECANOATE FORMULATIONS
KR102574139B1 (ko) 2016-07-07 2023-09-05 삼성전자주식회사 무선 충전 모드를 변경하는 장치 및 방법
EP3538074B1 (en) * 2016-11-11 2023-07-26 Western University Of Health Sciences Methods of treating upper tract urothelial carcinomas
SI3709979T1 (sl) 2017-11-17 2025-03-31 Evonik Operations Gmbh Postopek za pripravo obložene kapsule s trdo ovojnico
US10716774B1 (en) 2018-01-05 2020-07-21 Yale Pharmaceuticals LLC Pharmaceutical compositions containing isotretinoin with improved dissolution profile and enhanced stability
AU2019308326B2 (en) 2018-07-20 2025-07-31 Lipocine Inc. Liver disease
WO2020069450A1 (en) * 2018-09-28 2020-04-02 Joel Studin Transpore delivery of drugs and uses thereof
SI3968969T1 (sl) * 2019-05-15 2026-02-27 Evonik Operations Gmbh Postopek priprave napolnjenih kapsul s trdo lupino s prevlekami na osnovi kopolimera (met)akrilata s strojem za polnjenje kapsul
US12193993B2 (en) * 2019-05-15 2025-01-14 Evonik Operations Gmbh Process for preparing filled hard-shell capsules with cellulose or starch-based coatings with a capsule-filling machine
US20220265679A1 (en) * 2019-08-09 2022-08-25 Tesorx Pharma, Llc Proliposomal testosterone undecanoate formulations
CN110747271B (zh) * 2019-12-02 2023-07-18 延边大学 关于pci术后血管损伤-再狭窄程度的标记物
JP6945874B2 (ja) * 2019-12-24 2021-10-06 一般財団法人バイオダイナミックス研究所 経口投与用医薬組成物
CN111840240A (zh) * 2020-05-29 2020-10-30 仁和堂药业有限公司 一种非那雄胺制剂及其应用
CN112121003B (zh) * 2020-09-29 2022-02-01 江苏集萃新型药物制剂技术研究所有限公司 缓释制剂载药材料及其组合物、缓释制剂及其制备方法
EP4340838A4 (en) * 2021-05-19 2025-04-16 Alberto Paz ORALLY ADMINISTERED COMPOSITIONS FOR CANCER TREATMENT
CN114668719B (zh) * 2022-02-21 2023-06-16 广东食品药品职业学院 双氢睾酮混悬剂与双氢睾酮冻干粉及其制备方法
CN119053322A (zh) * 2022-09-16 2024-11-29 长春金赛药业有限责任公司 一种甾体类激素磷脂组合物及其制备方法
CN117018211B (zh) * 2023-07-31 2025-09-09 沈阳药科大学 一种睾酮-胆固醇前药及制备方法和应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4744989A (en) 1984-02-08 1988-05-17 E. R. Squibb & Sons, Inc. Method of preparing liposomes and products produced thereby
US5002936A (en) 1985-04-12 1991-03-26 Seymour Lieberman Lipophilic complexes of pharmacologically active inorganic mineral acid esters of organic compounds
US5049388A (en) * 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
CA1337397C (en) 1988-09-29 1995-10-24 Hideo Nakajima Emulsified composition
IE904098A1 (en) 1989-11-13 1991-05-22 Nova Pharm Corp Lipospheres for controlled delivery of substances
US20040175417A1 (en) 1990-10-19 2004-09-09 Gilead Sciences, Inc. Amphotericin B liposome preparation
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
JP3017906B2 (ja) 1993-10-08 2000-03-13 信越化学工業株式会社 腸溶性コーティング剤分散液
US6214375B1 (en) 1996-07-16 2001-04-10 Generex Pharmaceuticals, Inc. Phospholipid formulations
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6761901B1 (en) 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
US6858596B2 (en) * 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
WO2002051426A2 (en) 2000-12-22 2002-07-04 A Glenn Braswell COMPOSITIONS AND METHODS FOR TREATING SEXUAL DYSFUNCTIONS, IMPROVING SEXUAL ACTIVITY AND INCREASING TESTOSTERONE LEVELS, AND IMPROVING MUSCLE STRENGTH AND MASS
US6534080B2 (en) 2001-02-12 2003-03-18 Super Gen, Inc. Method for administering camptothecins via injection of pharmaceutical composition comprising coated particles of a camptothecin
US8658202B2 (en) * 2001-04-25 2014-02-25 Western University Of Health Sciences Coated drug delivery formulations
US6759058B1 (en) * 2001-04-25 2004-07-06 Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences Enteric-coated proliposomal formulations for poorly water soluble drugs
US20040115226A1 (en) 2002-12-12 2004-06-17 Wenji Li Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same
JO2505B1 (en) * 2003-03-14 2009-10-05 باير شيرنغ فارما اكتنجيسيلشافت Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
EP1624857A2 (de) 2003-05-12 2006-02-15 Novosom AG Injizierbare depots aus liposomalen aggregaten zur wirkstoffverabreichung
JP4787165B2 (ja) 2003-11-05 2011-10-05 エラン ファーマ インターナショナル，リミティド 表面安定剤としてペプチドを有するナノ粒子組成物
WO2006012502A2 (en) 2004-07-23 2006-02-02 Rigel Pharmaceuticals, Inc. Formulation of insoluble small molecule therapeutics in lipid-based carriers
WO2006062506A1 (en) * 2004-12-03 2006-06-15 Enzrel, Inc. Chitosan-coated liposome drug delivery of antioxidant or anti-inflammatory compounds
CA2631875A1 (en) 2005-12-06 2007-10-04 Rigel Pharmaceuticals, Inc. Formulation of insoluble small molecule therapeutics in lipid-based carriers
US20070154403A1 (en) 2006-01-05 2007-07-05 Thomas Skold Oral, Pulmonary and Transmucosal Delivery Composition
AU2007235463B2 (en) 2006-03-30 2012-11-22 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes
EP2146692A1 (en) * 2007-03-19 2010-01-27 Fresenius Kabi Oncology Limited Proliposomal and liposomal compositions
US11304960B2 (en) * 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
CN103228266B (zh) * 2010-10-29 2017-11-14 健康科学西部大学 三元混合物制剂
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
JP2014521752A (ja) 2011-08-18 2014-08-28 モノソル・アールエックス・エルエルシー ステロイドホルモンの送達システムおよびその調製方法

Also Published As

Publication number Publication date
TN2014000467A1 (en) 2016-03-30
CO7240373A2 (es) 2015-04-17
US20180303850A1 (en) 2018-10-25
US20150157572A1 (en) 2015-06-11
JP2017061552A (ja) 2017-03-30
KR20150032939A (ko) 2015-03-31
JP6208842B2 (ja) 2017-10-04
CN108096192A (zh) 2018-06-01
ZA201509340B (en) 2018-05-30
US20160375036A1 (en) 2016-12-29
EP2846781A4 (en) 2016-03-30
UA115058C2 (uk) 2017-09-11
AU2013259509B2 (en) 2017-09-07
EA028809B1 (ru) 2018-01-31
US9445995B2 (en) 2016-09-20
NZ721900A (en) 2018-01-26
MY175305A (en) 2020-06-18
US20140112986A1 (en) 2014-04-24
EA201492047A1 (ru) 2015-05-29
HK1210409A1 (en) 2016-04-22
WO2013170012A3 (en) 2015-06-04
DOP2015000026A (es) 2015-06-15
GEP201706754B (en) 2017-10-25
TWI664982B (zh) 2019-07-11
NZ702634A (en) 2016-09-30
MA37610A1 (fr) 2016-07-29
CN104780914A (zh) 2015-07-15
HK1255929A1 (zh) 2019-09-06
EP2846781B1 (en) 2019-10-30
CN104780914B (zh) 2018-02-09
BR112014027942A2 (pt) 2017-06-27
TW201350140A (zh) 2013-12-16
MA37610B1 (fr) 2017-07-31
US9623033B2 (en) 2017-04-18
PH12014502498A1 (en) 2014-12-22
CR20140561A (es) 2015-02-12
AU2017272249A1 (en) 2017-12-21
SG10201702240TA (en) 2017-05-30
JP6055088B2 (ja) 2016-12-27
JP2015520751A (ja) 2015-07-23
AP2014008099A0 (en) 2014-12-31
AU2013259509A1 (en) 2015-01-15
IL235464A0 (en) 2014-12-31
AU2017272249B2 (en) 2019-01-31
PE20150203A1 (es) 2015-02-01
EA201791738A1 (ru) 2018-03-30
ECSP14030572A (es) 2015-11-30
JP2018021062A (ja) 2018-02-08
US20170065614A1 (en) 2017-03-09
US9844557B2 (en) 2017-12-19
EP2846781A2 (en) 2015-03-18
JP6368020B2 (ja) 2018-08-01
ZA201408996B (en) 2017-08-30
WO2013170012A2 (en) 2013-11-14
CA2872779A1 (en) 2013-11-14
SG11201407349UA (en) 2014-12-30
US8957053B2 (en) 2015-02-17
IL235464B (en) 2019-09-26
TWI614035B (zh) 2018-02-11
MX367123B (es) 2019-08-06
MX2014013450A (es) 2015-05-11
HK1211499A1 (en) 2016-05-27
AR091006A1 (es) 2014-12-30
IN2014DN10383A (es) 2015-08-14
TW201831169A (zh) 2018-09-01

Similar Documents

Publication Publication Date Title
CL2014003034A1 (es) Dispersion en polvo proliposomal que comprende terstosterona, colesterol y al menos un fosfolipido; una forma de dosificacion oral; y su uso en una terapia de testosterona
IL267560A (en) R-spondin compounds and methods of using them
ZA201405819B (en) Lupane triterpenoid derivatives and pharmaceutical use thereof
CO6900149A2 (es) Una composición farmacéutica que comprende los fitocanabinoides canabidivarina (cbdv) y canabidiol (cbd)
SMT202100509T1 (it) Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
EP2670687A1 (en) Capsules and dispensing machine
EP2739288A4 (en) PROGESTERONE-CONTAINING ORAL PHARMACEUTICAL FORMS AND RELEVANT PROCEDURES
CL2015000345A1 (es) Uso de una combinación para el melanoma que comprende la administración de cobimetinib y vemurafenib.
EP2679035A4 (en) TEMPORARY RESTRICTIONS AND BACK RETURN
IL235820A0 (en) Dosage forms containing apixaban and a matrix forming agent
GB2498422B (en) Paste dispenser and paste receiving pouches
EP3022320A4 (en) Whole-genome and targeted haplotype reconstruction
HRP20181172T1 (hr) Derivati pirazolpirimidina supstituirani na poziciji 4, te njihova uporaba u proizvodnji lijekova
CO7061069A2 (es) Glucosaminoglucanos no anticogulantes que comprenden una unidad de repetición de disacárido y su uso médico
PL2613815T3 (pl) Dozownik materiałów lotnych i jego dozujące sito
IL228436A0 (en) Pyridopyrazine history and their use
EP2941634A4 (en) Dynamic dose reduction in x-ray inspection
SG11201403308QA (en) Pharmaceutical preparation comprising brexpiprazole and substituted beta - cyclodextrin
EP3071563A4 (en) Anti-cancer agents and preparation thereof
PL2810755T3 (pl) Wirnik mieszający do zastosowania w mieszarce zamkniętej oraz mieszarka zamknięta zawierająca wirnik mieszający
IL235830A0 (en) New dosage and formulation
HUP1300564A2 (en) Pharmaceutical composition comprising a cholesterol biosynthesis inhibitor and a cholesterol absorption inhibitor
FR2958166B1 (fr) Compositions pharmaceutiques fortement dosees en biotine
HUE042638T2 (hu) Egy szilárd nanorészecskébõl és legalább egy antigénbõl álló gyógyszerészeti összetétel intracelluláris kórokozó elleni kezelésre
ES1077692Y (es) Pantalla oral para tratamientos de ortodoncia y similares